Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NASDAQ:MIRM NASDAQ:RARE NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$58.97-1.3%$53.75$1.16▼$14.10$2.56B-0.12189,291 shs373,398 shsMIRMMirum Pharmaceuticals$52.24+0.4%$49.88$36.20▼$54.78$2.58B0.94368,843 shs313,554 shsRAREUltragenyx Pharmaceutical$28.46+0.1%$33.84$25.81▼$60.37$2.69B0.253.30 million shs1.65 million shsXNCRXencor$7.95-0.4%$8.68$7.16▼$27.24$567.94M0.89603,431 shs595,241 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics0.00%-2.71%+7.71%+21.34%+37.65%MIRMMirum Pharmaceuticals+0.42%+1.46%+4.63%+27.47%+32.66%RAREUltragenyx Pharmaceutical+0.07%+3.08%-27.38%-18.82%-43.61%XNCRXencor-0.38%-11.96%-5.41%-6.03%-58.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals3.9686 of 5 stars3.60.00.04.23.32.50.6RAREUltragenyx Pharmaceutical4.504 of 5 stars4.51.00.03.83.82.50.6XNCRXencor3.4965 of 5 stars3.40.00.03.91.90.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 3.13Buy$65.5025.38% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$83.25192.52% UpsideXNCRXencor 2.75Moderate Buy$28.00252.20% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, GMTX, RARE, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$80.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/11/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMIRMMirum Pharmaceuticals$336.89M7.68N/AN/A$4.70 per share11.11RAREUltragenyx Pharmaceutical$560.23M4.80N/AN/A$2.76 per share10.31XNCRXencor$110.49M5.12N/AN/A$9.63 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%8/5/2025 (Estimated)XNCRXencor-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%N/ALatest XNCR, GMTX, RARE, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31N/AN/AN/A$107.91 millionN/A8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/A$161.37 millionN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49MIRMMirum Pharmaceuticals1.323.223.04RAREUltragenyx PharmaceuticalN/A2.402.24XNCRXencor0.165.895.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%MIRMMirum PharmaceuticalsN/ARAREUltragenyx Pharmaceutical97.67%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%MIRMMirum Pharmaceuticals22.87%RAREUltragenyx Pharmaceutical5.50%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMIRMMirum Pharmaceuticals14049.53 million38.21 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableXNCRXencor28071.17 million67.45 millionOptionableXNCR, GMTX, RARE, and MIRM HeadlinesRecent News About These CompaniesXencor (XNCR) to Release Earnings on MondayAugust 3 at 2:17 AM | americanbankingnews.comShort Interest in Xencor, Inc. (NASDAQ:XNCR) Rises By 127,291.3%August 3 at 2:21 AM | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Short Interest UpdateAugust 2 at 1:59 PM | marketbeat.comXencor Appoints Raymond Deshaies, Ph.D., to Board of DirectorsJuly 31, 2025 | finance.yahoo.comAnalysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $28.00July 31, 2025 | americanbankingnews.comXencor (XNCR) Projected to Post Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comY Intercept Hong Kong Ltd Invests $528,000 in Xencor, Inc. (NASDAQ:XNCR)July 28, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 28, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?July 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?July 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?July 9, 2025 | marketbeat.comXencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo FinanceJune 29, 2025 | ca.finance.yahoo.comInsider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of StockJune 17, 2025 | insidertrades.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comWill Xencor (XNCR) Report Negative Q1 Earnings? What You Should KnowMay 1, 2025 | zacks.comWilliam Blair starts Xencor stock with Outperform ratingApril 23, 2025 | uk.investing.comWilliam Blair Initiates Coverage of Xencor (XNCR) with Outperform RecommendationApril 22, 2025 | msn.comXencor initiated with an Outperform at William BlairApril 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsMP Materials Stock Booms on New Government PositioningBy Gabriel Osorio-Mazilli | July 14, 2025View MP Materials Stock Booms on New Government PositioningNVIDIA: A Major Indicator Just Flashed Sell, But Should You?By Sam Quirke | July 30, 2025View NVIDIA: A Major Indicator Just Flashed Sell, But Should You?Top 5 Undervalued Dividend Stocks With Strong Payout PotentialBy Ryan Hasson | July 7, 2025View Top 5 Undervalued Dividend Stocks With Strong Payout PotentialXNCR, GMTX, RARE, and MIRM Company DescriptionsGemini Therapeutics NASDAQ:GMTX$58.97 -0.79 (-1.32%) As of 08/1/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$52.24 +0.22 (+0.42%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$52.22 -0.02 (-0.04%) As of 08/4/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Ultragenyx Pharmaceutical NASDAQ:RARE$28.46 +0.02 (+0.07%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$29.50 +1.04 (+3.65%) As of 05:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Xencor NASDAQ:XNCR$7.95 -0.03 (-0.38%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$9.20 +1.25 (+15.72%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
